Reverb Therapeutics develops bispecific antibodies that target endogenous cytokines to immune cells within the tumor microenvironment, enhancing localized immune activation for cancer treatment. This approach minimizes the toxicity associated with exogenously delivered cytokines, improving therapeutic outcomes for cancer patients.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Systemic cytokine therapies for cancer can cause severe toxicity due to widespread immune activation throughout the body. Traditional approaches to cancer immunotherapy often fail to achieve sufficient localized immune activation within the tumor microenvironment.
Solution
Reverb Therapeutics engineers bispecific antibodies that redirect endogenous cytokines to immune cells specifically within the tumor microenvironment. By targeting and delivering cytokines directly to the tumor site, Reverb's approach enhances localized immune activation while minimizing systemic exposure and associated toxicities. This targeted delivery aims to improve the therapeutic index of cytokine-based cancer treatments, leading to more effective and safer outcomes for patients. The bispecific antibodies are designed to bind both a specific cytokine and a target on immune cells within the tumor, creating a bridge that promotes localized immune stimulation. This strategy seeks to overcome the limitations of systemic cytokine administration by focusing the immune response where it is most needed.
Target Audience
The primary target audience includes cancer patients, oncologists, and pharmaceutical companies focused on developing novel immunotherapies.
Features
- Bispecific antibody platform for targeted cytokine delivery
- Selective engagement of immune cells within the tumor microenvironment
- Enhanced localized immune activation at the tumor site
- Minimized systemic cytokine exposure and toxicity